GlassScriptPhysician profile
Sarah Buchanan
NPI 1063626331
$8,733.99
in general payments reported to CMS, 2019-2025
25 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $85.88 · 2021: $786 · 2022: $55.61 · 2023: $4,027 · 2024: $3,427 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $1,671 · Food and Beverage: $1,613 · Gift: $22.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $1,670.75 |
| Food and Beverage | $1,612.60 |
| Gift | $22.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,415.57 | 2021-2024 | Da Vinci Surgical System, Davinci Xi |
| Sumitomo Pharma America, INC. | $259.21 | 2023-2025 | Myfembree |
| Biogen, INC. | $168.29 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $124.98 | 2022-2025 | Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $94.29 | 2023-2024 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Exeltis, USA INC. | $83.40 | 2023-2025 | Slynd |
| Pfizer INC. | $82.98 | 2023-2024 | |
| Organon LLC | $56.29 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $48.60 | 2024-2025 | Veozah |
| Applied Medical Resources Corporation | $40.20 | 2024 | |
| Inspire Medical Systems, INC. | $39.40 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $35.33 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $29.30 | 2025 | |
| Novo Nordisk INC | $28.39 | 2023 | |
| Myriad Genetic Laboratories, INC. | $28.10 | 2024 | Myrisk |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.38 | 2020 | |
| Therapeuticsmd, INC. | $26.74 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $24.51 | 2024 | Monoferric |
| Medtronic, INC. | $23.53 | 2023 | Truclear |
| Dexcom, INC. | $22.28 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $18.95 | 2024 | Prolia, Evenity |
| Alkermes, INC. | $16.15 | 2022 | |
| Neurocrine Biosciences, INC. | $15.12 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.85 | 2020 | |
| Lundbeck LLC | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.